Eli M. Wallace

Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen, Haley Hill, Alana Christie et al. · Nature · 2016 · 723 citations

Medicine, Cancer Biology, Oncology +10

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Hyejin Cho, Xinlin Du, James P. Rizzi et al. · Nature · 2016 · 461 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam et al. · Journal of Clinical Oncology · 2017 · 390 citations · Full text

Medicine, Oncology, Pharmacology +16

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Eli M. Wallace, James P. Rizzi, Guangzhou Han et al. · Cancer Research · 2016 · 329 citations

Medicine, Oncology, Pharmacology +17

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

James F. Blake, Rui Xu, Josef R. Bencsik et al. · Journal of Medicinal Chemistry · 2012 · 188 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16